<div id="readability-page-1"><div><p>Despite an already strong run, <strong>RxSight, Inc.</strong> (NASDAQ:RXST) shares have been powering on, with a gain of 28% in the last thirty days.    Still, the 30-day jump doesn't change the fact that longer term shareholders have seen their stock decimated by the 64% share price drop in the last twelve months.</p><p> In spite of the firm bounce in price, you could still be forgiven for feeling indifferent about RxSight's P/S ratio of 3.8x, since the median price-to-sales (or &#34;P/S&#34;) ratio for the Medical Equipment industry in the United States is also close to 3.5x.  However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.    </p> <p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p> <p><span> See our latest analysis for RxSight </span></p><figure><img height="650" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1640" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200"/><figcaption>NasdaqGM:RXST Price to Sales Ratio vs Industry December 12th 2025</figcaption></figure><h3> How Has RxSight Performed Recently? </h3><p> RxSight's revenue growth of late has been pretty similar to most other companies.   It seems that many are expecting the mediocre revenue performance to persist, which has held the P/S ratio back.  If you like the company, you'd be hoping this can at least be maintained so that you could pick up some stock while it's not quite in favour.     </p><p> Want the full picture on analyst estimates for the company? Then our <strong>free </strong>report on RxSight will help you uncover what's on the horizon.  </p><h2> Do Revenue Forecasts Match The P/S Ratio?  </h2><p> RxSight's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.  </p><p> Taking a look back first, we see that the company managed to grow revenues by a handy 11% last year.   The latest three year period has also seen an excellent 244% overall rise in revenue, aided somewhat by its short-term performance.  Therefore, it's fair to say the revenue growth recently has been superb for the company.   </p> <p> Looking ahead now, revenue is anticipated to climb by 3.3% per year during the coming three years according to the ten analysts following the company.  With the industry predicted to deliver 136% growth each year, the company is positioned for a weaker revenue result. </p><p> With this in mind, we find it intriguing that RxSight's P/S is closely matching its industry peers.  It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock.  These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.  </p> <h2> The Key Takeaway </h2><p> RxSight appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry      Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects. </p><p> Our look at the analysts forecasts of RxSight's revenue prospects has shown that its inferior revenue outlook isn't negatively impacting its P/S as much as we would have predicted.  At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long.  A positive change is needed in order to justify the current price-to-sales ratio.     </p><p> There are also other vital risk factors to consider and we've discovered <strong>2 warning signs for RxSight</strong> (1 makes us a bit uncomfortable!) that you should be aware of before investing here.  </p><p> Of course, <strong>profitable companies with a history of great earnings growth are generally safer bets</strong>. So you may wish to see this <strong>free</strong> collection of other companies that have reasonable P/E ratios and have grown earnings strongly. </p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

RXST

<p>RxSight, Inc. (NASDAQ:RXST) shares rose 28% in the last 30 days, despite a 64% drop over the past year. The company's P/S ratio of 3.8x aligns with the industry average, but revenue growth is expected to be moderate at 3.3% annually, compared to the industry's 136%. Investors may face disappointment if growth doesn't justify the current P/S ratio. Analysts suggest caution due to limited growth expectations and potential risk factors.</p>

RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues